David Posada
@davidposada.bsky.social
An evolutionary biologist working in cancer evolution. Single-cell genomics, bioinformatics, anything phylo (phylogenetics, phylogeography, phylodynamics).
Reposted by David Posada
The second is about potential fitness costs of cancer drug resistance, and how we might exploit them using approaches like adaptive therapy. (building on our work with @mlockley.bsky.social in ovarian cancer: aacrjournals.org/cancerres/ar...). Description here: www.icr.ac.uk/study-and-ca...
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
Carboplatin adaptive therapy improves treatment efficacy without increasing daily dose due to reduced fitness of drug-resistant populations, which can be tracked using cfDNA and could direct adaptive ...
aacrjournals.org
October 14, 2025 at 8:26 PM
The second is about potential fitness costs of cancer drug resistance, and how we might exploit them using approaches like adaptive therapy. (building on our work with @mlockley.bsky.social in ovarian cancer: aacrjournals.org/cancerres/ar...). Description here: www.icr.ac.uk/study-and-ca...
It was not something I heard, but something I saw: hope in their eyes
October 6, 2025 at 8:51 AM
It was not something I heard, but something I saw: hope in their eyes
Big congrats Monica! so well-deserved! 👏
September 23, 2025 at 5:50 PM
Big congrats Monica! so well-deserved! 👏
Very nice work @trevorgraham.bsky.social and colleagues!! 👏
September 11, 2025 at 6:25 AM
Very nice work @trevorgraham.bsky.social and colleagues!! 👏